“A founding father of the Cambridge biotechnology cluster says its leading innovators have come late to the life science funding feast in global terms, despite recent successes.

Having missed out in many respects on the primary party, Cambridge biotechs are set for a second coming with the world’s leading Big Pharma companies now camped on Cambridge’s doorstep.

Their presence should ensure that the city’s bio brainpower is finally rewarded in a new wave of investments focused on a larger slice of the cake rather than scattered crumbs, says Dr Andy Richards.”